Home Newsfeeds Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $37

Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $37

Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $33 to $37.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $33 to $37.

Ethereum Pips Bitcoin, Dogecoin: Analyst Says Crypto ‘More Eager’ To Break Upwards Amid Jackson Hole Anxiety

By Shivdeep Dhaliwal

August 24, 9:30 PM

The two largest coins traded higher on Wednesday evening as the global cryptocurrency market cap fell 0.4% to $1 trillion.

$DOGE

Is Microsoft Heading Over The $300 Mark? The Bull, Bear Case For The Tech Giant

By Melanie Schaffer

April 6, 10:59 AM

Microsoft Corporation (NASDAQ: MSFT) opened lower on Thursday ahead of key U.S. jobs data expected Friday.

MSFT

Investor Sentiment Improves; Dow Jumps Over 150 Points

By Avi Kapoor

February 15, 3:39 AM

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Wednesday. U.S. stocks closed higher on Wednesday, after recording sharp losses in the previous session.

ABNB

Analyst Ratings

What 9 Analyst Ratings Have To Say About NextEra Energy

By Benzinga Insights

October 20, 11:05 AM

Analysts have provided the following ratings for NextEra Energy (NYSE:NEE) within the last quarter:

NEE

Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $37

Related Posts

Ethereum Pips Bitcoin, Dogecoin: Analyst Says Crypto ‘More Eager’ To Break Upwards Amid Jackson Hole Anxiety

Is Microsoft Heading Over The $300 Mark? The Bull, Bear Case For The Tech Giant

Investor Sentiment Improves; Dow Jumps Over 150 Points

What 9 Analyst Ratings Have To Say About NextEra Energy